N. Tarazona
Universitat de València · 12 works · 1,058 citations · h-index 4
Top works
- ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group
- Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer
- Enhancing precision oncology: the role of molecular tumor boards in early identification and targeted treatment of ESCAT II-III alterations
- Minimal residual disease in gastroesophageal adenocarcinoma: the search for the invisible
- 420P Minimal residual disease detection and tracking tumour evolution using ctDNA in stage I-III colorectal cancer patients
- 464P Exome sequencing of ctDNA portrays the mutational landscape of patients with relapsing colon cancer and indicates new actionable targets
- Whole-exome ctDNA sequencing reveals intratumoral heterogeneity and drivers of relapse in locally advanced head and neck cancer
- Interventional strategies to address burnout in young medical oncologists: results from the Resilience-Spanish Society of Medical Oncology (SEOM) Study and a university hospital experience in Spain
- P3.03.45 KRAS Mutations Shape an Oxidative, Immune-Cold Tumor Microenvironment Driving Chemo-Immunotherapy Resistance in Advanced NSCLC
- 406MO Sequencing paired tumor DNA and white blood cells (WBCs) increases sensitivity to track plasma circulating tumor DNA (ctDNA) for detecting minimal residual disease (MRD) in localized colon cancer (CC)
- ctDNA-guided adjuvant therapy in stage II colon cancer: a step forward, but not the final word
- 1201P The role of a mini tumour mutational burden (TMB) score generated with a customized NGS panel to predict benefit from immunotherapy